Ataibeckley Inc. · NASDAQ:ATAI
Ataibeckley — Technical Presentation (February 2026)
15 slides from Ataibeckley's technical presentation, Feb 26, 2026
Slide 1: EMP-01 (R-MDMA) Phase 2a Top Line Results in Social Anxiety Disorder
February 26, 2026 EMP-01 (R-MDMA)Phase 2a Top Line Results in Social Anxiety Disorder (SAD)
Slide 2: Disclaimer and Forward-Looking Statements
The following disclaimer applies to this Presentation. For the purposes of this disclaimer, “Presentation” means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meet
Slide 3: Social anxiety disorder prevalence and unmet need
3 12% Lifetime prevalence in the US2 (affects 5-6x more people than TRD) 0 Novel molecules for SAD in 20+ years Sources: 1. NIMH, “Social Anxiety Disorder.” (2025). *Total US population is estimated ~347 MM and total US adult population is estimated ~260 MM (75% of total). 2. Harvard Medical School,
Slide 4: EMP-01 Phase 2a Study Design
4 Abbreviations: LSAS = Liebowitz Social Anxiety Scale; PBO = Placebo; PK = Pharmacokinetics; SAD = Social Anxiety Disorder Exploratory Phase 2a, randomized, placebo-controlled study assessing safety, tolerability, and efficacy of 2 doses of EMP-01 in 70 adults with SAD EMP-01 Phase 2a Study Design
Slide 5: Baseline characteristics were well balanced across arms
Baseline characteristics were well balanced across armsPopulation: ITT 5 Source: Table 14.1.1.6 Demographics and Baseline Characteristics (Intent-to-Treat Population). Abbreviations: BMI=Body Mass Index; CGI-S = Clinical Global Impression-Severity; LSAS = Liebowitz Social Anxiety Scale; SD = Standar
Slide 6: Generally favorable and manageable safety and tolerability profile
Generally favorable and manageable safety and tolerability profile 6 Source: 14.3.1.1 Summary of All TEAEs with Risk Differences (Safety Population), Source: Table 14.3.1.7 Incidence of TEAEs by Maximum Severity, System Organ Class and Preferred Term (Safety Population). 1 TEAEs are defined as adver
Slide 7: Drug-related TEAEs were in line with expected psychedelic profile
Drug-related TEAEs were in line with expected psychedelic profile 7 Source: Safety: Table 2. Incidence of Common (≥15%) Non-Serious TEAEs by System Organ Class and Preferred Term (Population: Safety), Source: Safety: 14.3.1.8 Incidence of TEAEs by Strongest Relationship, System Organ Class and Prefe
Slide 8: Unique opportunity for EMP-01 to support mindset shift to engage in treatment
8 Unique opportunity for EMP-01 to support mindset shift to engage in disease modifying treatment Repeat exposure leading to behavior change1 Treatment is difficult for SAD patients to engage with as it requires repeat exposure to social situations SAD patient Source: 1. Hofmann SG, Otto MW. Cogniti
Slide 9: EMP-01 showed clinically meaningful improvement across the LSAS
9 Source: Efficacy: 14.2.1.2 Mixed Model for Repeated Measures (MMRM) of Liebowitz Social Anxiety Scale Total Score Change from Baseline to Day 43 with Standardized Effect Sizes. (Population: mITT n=70 ). Abbreviations: LS = Least Square; LSAS = Liebowitz Social Anxiety Scale; LSMD = Least Squares M
Slide 10: Meaningful improvements across both fear and avoidance domains
10 Source: Table 14.2.1.1 Summary and Change from Baseline to Day 29 and Day 43 of Liebowitz Social Anxiety Scale Total and Subscale Scores (Modified Intent-to-Treat Population). Abbreviations: LSAS = Liebowitz Social Anxiety Scale; SAD = Social Anxiety Disorder; SD = Standard Deviation LSAS Sub-Sca
Slide 11: CGI-I responder analysis supported LSAS findings
11 1. One patient in the placebo arm had a missing value at Day 43 on the CGI-I Responder Assessment. Abbreviations: CGI-I = Clinical Global Impression-Improvement; CI = Confidence Interval; LSAS = Liebowitz Social Anxiety Scale CGI-I Responder Placebo (N=351) EMP-01 225mg (N=35) Yes n (%) 5 (14.7)
Slide 12: EMP-01-201: Clinical activity benchmarking vs. approved SAD therapies
EMP-01-201: Clinical activity benchmarking vs. approved SAD therapies 12 Sources: 1. Williams et al., Pharmacotherapy for social anxiety disorder (SAnD) (Review). (2017). 2. Davis et al., Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. (2014). 3. van der Linde
Slide 13: EMP-01 produced a robust psychedelic experience with distinct profile
13 1. Presented data from EMP-01 225mg (n=35) and placebo (n=35) from Ph2a study. 2. Goodwin, G. M. et al. (2025). The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. (2025). 3. Schmid Y. et al. (2020) Acute subjective effects in LSD- and MDMA-assisted
Slide 14: Exploratory Phase 2a study demonstrated feasibility, safety and patient acceptability
14 An exploratory Phase 2a study demonstrated feasibility, generally well tolerated safety profile, and patient acceptability Successfully evaluated EMP-01 in 70 adults with marked–severe SAD across 7 UK sites in 7 months Strong adherence and retention through the primary endpoint Placebo-adjusted i
Slide 15: Thank You
@AtaiBeckley Thank You